- Tension: A woman on antidepressants for nineteen years experienced meaningful relief from a single twenty-minute DMT session — and she’s not an anomaly. Clinical trials are producing results that challenge everything we assumed about how long depression treatment should take.
- Noise: The hype cycle wants DMT to be a “reset button” for the brain, while skeptics dismiss it as another overpromised psychedelic. Both narratives miss the critical nuance: DMT without structured psychotherapy isn’t a treatment, and the serotonin model it’s quietly replacing was never the full picture.
- Direct Message: DMT isn’t offering people a new self — it’s restoring the brain’s capacity to adapt, process, and recognize the self that depression buried. The breakthrough isn’t pharmacological novelty; it’s a long-overdue reckoning with what depression actually is.
To learn more about our editorial approach, explore The Direct Message methodology.
Elaine Marsh, a 51-year-old former school counselor in Bristol, England, had been on antidepressants for nineteen years. Not the same one — she’d cycled through seven different SSRIs and SNRIs, each one promising something the last one couldn’t deliver. She described her depression to me not as sadness but as a kind of perceptual narrowing — like looking at the world through a paper towel tube. “I could see my life,” she said. “I just couldn’t feel it.” Last autumn, Elaine enrolled in a clinical trial at a London research hospital. A nurse placed an IV in her arm and — over the course of about twenty minutes — administered a synthetic form of DMT, the psychoactive compound found in ayahuasca. Within hours, something shifted. Within weeks, her depression scores had dropped by more than half.
Her psychiatrist was stunned. Her husband was cautious. Elaine herself wasn’t sure what to make of it — except that for the first time in nearly two decades, the paper towel tube was gone.
Stories like Elaine’s are emerging with increasing frequency from clinical research sites, and they’re forcing a reckoning with how we think about both depression and the tools we use to treat it. As we’ve covered in detail, DMT — N,N-dimethyltryptamine — is no longer a fringe curiosity whispered about in retreat circles. It’s now the subject of rigorous Phase II clinical trials, and the results are generating real scientific excitement.
But excitement, in medicine, is a complicated emotion. It usually arrives attached to something we don’t fully understand yet.
The most talked-about trial comes from Small Pharma (now Cybin), whose 2023 results published in Molecular Psychiatry showed that a single intravenous dose of SPL026 — their proprietary DMT formulation — combined with psychotherapy produced rapid and sustained reductions in depression severity. Participants with major depressive disorder showed significant improvement at two weeks, and many maintained those gains at three months. The speed alone is remarkable. Most conventional antidepressants take four to six weeks to reach full effect — and that’s if they work at all. For the roughly 30% of depression patients classified as “treatment-resistant,” those weeks often stretch into months, then years, then decades of what clinicians politely call “medication optimization” and patients less politely call limbo.
What makes DMT particularly interesting — and particularly disruptive — is the brevity of the experience. Unlike psilocybin, which requires a five-to-six-hour supervised session, or ketamine infusions that demand regular repetition, a DMT session lasts roughly 20 to 30 minutes. This has enormous implications for scalability. Therapist time is the bottleneck in every psychedelic-assisted therapy model, and DMT’s compressed timeline could radically change the economics of treatment.
James Okoro, a 38-year-old software developer in Toronto, has been tracking these developments with the obsessive attention of someone for whom the research is personal. His mother — who lives in Lagos — has struggled with severe depression for most of his adult life, cycling through medications that are either unavailable, unaffordable, or ineffective in her context. “When I read about a treatment that works in twenty minutes with lasting effects,” he told me, “I don’t see a psychedelic. I see access.” That distinction — between the substance and its potential — is one that researchers are increasingly trying to articulate. As recent reporting has explored, the conversation around DMT is shifting from “is this legitimate?” to “how do we implement this responsibly?”
But implementation requires understanding mechanism, and that’s where things get genuinely complicated.
The prevailing theory — what researchers call the “neural plasticity hypothesis” — suggests that DMT and similar psychedelics promote rapid neuroplasticity, essentially helping the brain form new connections and break out of the rigid, repetitive thought patterns that characterize depression. A 2023 study in PNAS demonstrated that psychedelics can increase dendritic spine density in cortical neurons — structural changes that correlate with improved mood and cognitive flexibility. The brain, in a sense, becomes briefly more moldable. More willing to reorganize.
This is where the cultural narrative gets tricky. There’s a temptation — especially in wellness-adjacent media — to frame DMT as a “reset button” for the brain. Pop a psychedelic, reboot your consciousness, emerge healed. It’s a seductive story. It’s also dangerously reductive. Dr. Carol Routledge, Chief Scientific Officer at Small Pharma, has been careful to emphasize that DMT alone isn’t the treatment — DMT combined with structured psychotherapy is the treatment. The drug opens a window. The therapy is what happens while the window is open.
This distinction matters more than most reporting acknowledges. Nadira Patel, a 44-year-old psychiatrist in Melbourne who has been following the trials closely, put it bluntly: “We’ve seen what happens when we separate a powerful pharmacological agent from its therapeutic context. We call it the opioid crisis.” She’s not equating DMT with opioids — the pharmacology is entirely different, and DMT shows no signs of addictive potential — but her point about context is sharp. A compound that temporarily dissolves the ego’s defenses is only therapeutic if there’s someone trained waiting on the other side to help you make sense of what you find.
And what people find isn’t always comfortable. Several trial participants have reported experiences that were profoundly challenging — encounters with grief they’d suppressed, memories they’d walled off, emotional material that felt almost unbearable in the moment. This is what psychedelic researchers call “emotional processing” — what the rest of us might call being forced to look at something you’ve spent years avoiding. One first-person account we published captured this with striking honesty — the aftermath wasn’t a miracle, but it was something the person hadn’t experienced in decades: recognition of their own reflection.
That word — recognition — keeps surfacing in these conversations. Not euphoria. Not transcendence. Recognition. As if depression doesn’t just make you feel bad — it makes you lose track of who you were before the feeling bad started. And what DMT may be offering, at least for some people, isn’t a new self but a reintroduction to an older one.
The skepticism, of course, is warranted and necessary. Phase II trials are small. Placebo controls in psychedelic research are notoriously difficult — it’s hard to blind a participant to whether they just had a reality-dissolving experience or received saline. Publication bias, hype cycles, and the gravitational pull of venture capital all distort the signal. Even promising small trials need to be held with appropriate caution. We’ve been burned before — by the overpromise of ketamine clinics, by the MDMA trial controversies, by every compound that was going to revolutionize psychiatry until it didn’t.
But there’s a difference between healthy skepticism and the reflexive dismissal that has historically greeted psychedelic research. For decades, the classification of these compounds as Schedule I substances — deemed to have no accepted medical use — created a research vacuum that had nothing to do with science and everything to do with politics. The fact that we’re now able to study DMT in rigorous clinical settings at all represents a kind of institutional thawing that took fifty years.
What’s emerging from that thaw is something more nuanced than “psychedelics cure depression” — and more honest than “they don’t work.” What’s emerging is a picture of depression itself as something more complex than a chemical imbalance to be corrected. The serotonin model — the foundation on which SSRIs were built — has been quietly crumbling for years, and in its place, researchers are groping toward a more systemic understanding. Depression may be less about having too little of one neurotransmitter and more about the brain losing its capacity to adapt — to form new patterns, to process emotional material, to remain flexible in the face of suffering.
If that’s true — and the evidence is increasingly pointing that way — then a treatment that temporarily restores that flexibility isn’t a shortcut. It’s addressing the actual problem.
Elaine Marsh is seven months out from her DMT session now. She’s still on a low dose of one antidepressant — her psychiatrist didn’t want her to change everything at once. She told me she doesn’t feel transformed. She feels — and she paused for a long time before choosing this word — available. Available to her husband. Available to her grown children. Available to the ordinary texture of a Tuesday morning, the kind she used to just endure.
That might not sound like much. But for someone who spent nineteen years behind a paper towel tube, availability is everything. It’s not the promise of a new life. It’s the quiet return of the one you already had — the one depression convinced you was gone for good.
Feature image by RDNE Stock project on Pexels
